leuprorelin acetate (DKF-MA102) / Dongkook Pharma - LARVOL DELTA

Real-world analysis of leuprorelin acetate microspheresbased neoadjuvant therapy for patients with high-risk prostate cancer (Front Oncol) - "This retrospective study included 53 patients with high-risk prostate cancer who received Boennuokang leuprorelin acetate microspheres as neoadjuvant therapy and laparoscopic radical prostatectomy....The median prostate-specific antigen (PSA) was 34.1 ng/mL before neoadjuvant therapy and reduced to 0.8 ng/mL after neoadjuvant therapy (P<0.001). Testosterone showed a decreased tendency after neoadjuvant therapy, but without statistical significance (P=0.185). After surgery, 36 (67.9%) patients had negative surgical margin. The median (interquartile range) prostate volume reduced from 40.5 (33.4-55.2) mL before neoadjuvant therapy to 30.2 (25.2-40.2) mL after neoadjuvant therapy (P<0.001)."

Retrospective data • Prostate Cancer

Kangyuan Pharmaceutical Group Co., Ltd.’s announcement on Leuprorelin Acetate Microspheres for Injection passing the consistency evaluation [Google translation] (Stockstar) - "Recently, Shanghai Livzon Pharmaceutical Co., Ltd...received the 'Notice of Approval of Supplementary Drug Application' (Certificate No.: Quality and Efficacy Consistency Evaluation of Generic Drugs) approved and issued by the State Drug Administration."

China approval • Breast Cancer • Oncology • Prostate Cancer

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer (clinicaltrials.gov) - P3 | N=154 | Recruiting | Sponsor: Dongkook Pharmaceutical Co., Ltd.

New P3 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor